APA (7th ed.) Citation

Ogbuagu, O., Ruane, P. J., Podzamczer, D., Salazar, L. C., Henry, K., Asmuth, D. M., . . . Spinner, C. D. (2021). Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: Week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet HIV, 8(7), e397. https://doi.org/10.1016/S2352-3018(21)00071-0

Chicago Style (17th ed.) Citation

Ogbuagu, Onyema, et al. "Long-term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Vs Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Week 96 Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet HIV 8, no. 7 (2021): e397. https://doi.org/10.1016/S2352-3018(21)00071-0.

MLA (9th ed.) Citation

Ogbuagu, Onyema, et al. "Long-term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Vs Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Week 96 Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet HIV, vol. 8, no. 7, 2021, p. e397, https://doi.org/10.1016/S2352-3018(21)00071-0.